# A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation

> **NCT06836024** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Constipation - Functional
- Constipation
- Constipation Aggravated

## Interventions

- **DIETARY_SUPPLEMENT:** Actazin chewable tablet
- **DRUG:** PEG 3350
- **OTHER:** Chewable Tablet
- **OTHER:** Maltodextrin (Placebo)

## Key facts

- **NCT ID:** NCT06836024
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-02-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06836024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06836024, "A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06836024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*